keyword
MENU ▼
Read by QxMD icon Read
search

survival improvement in patients with pancreatic cancer

keyword
https://www.readbyqxmd.com/read/28635511/the-immunohistochemical-expression-mta-1-protein-and-its-prognostic-value-in-pancreatic-cancer
#1
Efstathios T Pavlidis, Maria Lambropoulou, Nikolaos G Symeonidis, Constantinos Anagnostopoulos, Alexandra Tsaroucha, Athanasia Kotini, Christina Nikolaidou, Anastasia Kiziridou, Constantinos Simopoulos
Purpose/aim: To examine with immunohistochemical assay MTA1 protein expression levels in pancreatic cancer tissues defining its prognostic value. MATERIAL AND METHODS: The specimens derived from 51 patients who underwent surgery. The levels of MTA1 protein were compared with the age of the patients, their survival, and prognosis. Also, we studied clinical and histopathological factors such as the degree of tumor differentiation and its stage in correlation with MTA1 protein levels. In parallel, there was correlation between the expression of the ΜΤΑ1 protein and the aforementioned factors regarding survival rate...
February 10, 2017: Journal of Investigative Surgery: the Official Journal of the Academy of Surgical Research
https://www.readbyqxmd.com/read/28634650/a-randomized-phase-ii-study-of-gemcitabine-plus-z-360-a-cck2-receptor-selective-antagonist-in-patients-with-metastatic-pancreatic-cancer-as-compared-with-gemcitabine-plus-placebo
#2
Makoto Ueno, Chung Pin Li, Masafumi Ikeda, Hiroshi Ishii, Nobumasa Mizuno, Taketo Yamaguchi, Tatsuya Ioka, Do Youn Oh, Wataru Ichikawa, Takuji Okusaka, Yutaka Matsuyama, Daichi Arai, Li Tzong Chen, Young Suk Park, Junji Furuse
BACKGROUND: We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS: Patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups. Patients received 1000 mg/m(2) gemcitabine for each cycle and Z-360 tablets of 60 mg (GZ 60 mg group), 120, 240 mg or placebo tablets (Gem group) orally twice daily...
June 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28626429/the-potential-for-circulating-tumor-cells-in-pancreatic-cancer-management
#3
REVIEW
Michael Pimienta, Mouad Edderkaoui, Ruoxiang Wang, Stephen Pandol
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit. Though much effort has gone into finding new ways for early diagnosis and treatment, average patient survival has only been improved in the order of months. Circulating tumor cells (CTCs) are shed from primary tumors, including pre-malignant phases. These cells possess information about the genomic characteristics of their tumor source in situ, and their detection and characterization holds potential in early cancer diagnosis, prognosis, and treatment...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28624799/effects-of-metformin-on-survival-outcomes-of-pancreatic-cancer-a-meta-analysis
#4
Yi-Wei Dong, Yan-Qiang Shi, Li-Wen He, Xi-Yu Cui, Pei-Zhu Su
BACKGROUND AND AIM: Recent epidemiological studies indicated that metformin might improve the survival of various cancers. However, its benefit on pancreatic cancer was controversial. METHODS: We performed this meta-analysis to investigate the benefit of metformin on pancreatic cancer. A comprehensive literature search was performed through PubMed, Cochrane Library and Embase. Relative risk (RR) and hazard ratio (HR) with 95% confidence interval (CI) were pooled...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28624029/effect-of-complications-on-oncologic-outcomes-after-pancreaticoduodenectomy-for-pancreatic-cancer
#5
Anh-Thu Le, Bin Huang, Dima Hnoosh, Hayder Saeed, Sean P Dineen, Peter J Hosein, Eric B Durbin, Mahesh Kudrimoti, Patrick C McGrath, Ching-Wei D Tzeng
BACKGROUND: Although adjuvant therapy (AT) is a necessary component of multimodality therapy for pancreatic ductal adenocarcinoma (PDAC), its application can be hindered by post-pancreaticoduodenectomy (PD) complications. The primary aim of this study was to evaluate the impact of post-PD complications on AT utilization and overall survival (OS). METHODS: Patients undergoing PD without neoadjuvant therapy for stages I-III PDAC at a single institution (2007-2015) were evaluated...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28624015/imaging-modalities-in-the-diagnosis-of-pancreatic-adenocarcinoma-a-systematic-review-and-meta-analysis-of-sensitivity-specificity-and-diagnostic-accuracy
#6
James Toft, William J Hadden, Jerome M Laurence, Vincent Lam, Lawrence Yuen, Anna Janssen, Henry Pleass
BACKGROUND: Pancreatic cancer, primarily pancreatic ductal adenocarcinoma (PDAC), accounts for 2.4% of cancer diagnoses and 5.8% of cancer death annually. Early diagnoses can improve 5-year survival in PDAC. The aim of this systematic review was to determine the sensitivity, specificity and diagnostic accuracy values for MRI, CT, PET&PET/CT, EUS and transabdominal ultrasound (TAUS) in the diagnosis of PDAC. METHODS: A systematic review was undertaken to identify studies reporting sensitivity, specificity and/or diagnostic accuracy for the diagnosis of PDAC with MRI, CT, PET, EUS or TAUS...
July 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28621885/multiagent-induction-chemotherapy-followed-by-chemoradiation-is-associated-with-improved-survival-in-locally-advanced-pancreatic-cancer
#7
Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido-Laguna, George M Cannon
BACKGROUND: The role of chemoradiotherapy (CRT) in locally advanced pancreatic cancer (LAPC) is uncertain after multiple randomized clinical trials have yielded mixed results. The authors used the National Cancer Database (NCDB) to determine whether CRT yields a survival benefit compared with chemotherapy alone (CT). METHODS: Patients with nonmetastatic LAPC diagnosed during 2004 through 2014 were identified in the NCDB. Patients who received CT were compared with those who received CRT using chi-square analysis...
June 16, 2017: Cancer
https://www.readbyqxmd.com/read/28619830/differential-and-joint-effects-of-metformin-and-statins-on-overall-survival-of-elderly-patients-with-pancreatic-adenocarcinoma-a-large-population-based-study
#8
Jian-Yu E, Shou-En Lu, Yong Lin, Judith M Graber, David Rotter, Lanjing Zhang, Gloria M Petersen, Kitaw Demissie, Grace Lu-Yao, Xiang-Lin Tan
BACKGROUND: Published evidence indicates that individual use of metformin and statin is associated with reduced cancer mortality. However, their differential and joint effects on pancreatic cancer survival are inconclusive. METHODS: We identified a large population-based cohort of 12,572 patients aged 65 years or older with primary pancreatic ductal adenocarcinoma (PDAC) diagnosed between 2008 and 2011 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database...
June 15, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28618967/association-of-lysosomal-protein-transmembrane-4-beta-gene-polymorphism-with-pancreatic-carcinoma-susceptibility-in-the-chinese-population
#9
Bing Wang, Shan Wang, Guowei Liang, Jianjun Xu, Rouli Zhou, Qingyun Zhang
Pancreatic carcinoma is an aggressive malignancy with particularly low 5-year survival rate. In order to improve the dismal survival rate, identification of new potential susceptibility risk factors for the prevention and early detection of pancreatic carcinoma is of utmost importance. Lysosomal protein transmembrane 4 beta has two alleles designated as LAPTM4B*1 and LAPTM4B*2. The aim of this study was to investigate the association between lysosomal protein transmembrane 4 beta gene polymorphism and the risk of pancreatic carcinoma in China...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28615506/modified-protocol-for-enhanced-recovery-after-surgery-is-beneficial-for-chinese-cancer-patients-undergoing-pancreaticoduodenectomy
#10
Xiaxing Deng, Xi Cheng, Zhen Huo, Yuan Shi, Zhijian Jin, Haoran Feng, Yue Wang, Chenlei Wen, Hao Qian, Ren Zhao, Weihua Qiu, Baiyong Shen, Chenghong Peng
Radical surgical resection remains the only effective treatment for advanced pancreatic cancer. Effective protocols for recovery from post-operative complications that result in high rates of morbidity and mortality are therefore essential. The enhanced recovery after surgery (ERAS) protocol is an interdisciplinary multimodal concept based on modern anesthesia and analgesia combined with other fast rehabilitation parameters. It was first applied in the field of elective colorectal surgery, and eventually extended to several surgical diseases...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28611107/il-6-receptor-blockade-enhances-chemotherapy-efficacy-in-pancreatic-ductal-adenocarcinoma
#11
Kristen B Long, Graham Tooker, Evan Tooker, Santiago Lombo Luque, Jae W Lee, Xiaoqing Pan, Gregory L Beatty
Inflammation mediated by activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling is a major cause of chemotherapy resistance in cancer. We studied the impact of selectively blocking the IL-6 receptor (IL6R) as a strategy to inhibit IL-6-induced STAT activation and to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC). To do this, STAT activation was investigated in tumors arising spontaneously in LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1Cre (KPC) mice...
June 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28603091/gemcitabine-based-combination-therapy-compared-with-gemcitabine-alone-for-advanced-pancreatic-cancer-a-meta-analysis-of-nine-randomized-controlled-trials
#12
Shui-Fang Jin, Zhao-Kun Fan, Lei Pan, Li-Ming Jin
BACKGROUND: Pancreatic cancer is one of the most aggressive malignancies and chemotherapy is an effective strategy for advanced pancreatic cancer. Gemcitabine (GEM) is one of first-line agents. However, GEM-based combination therapy has shown promising efficacy in patients with advanced pancreatic cancer. This meta-analysis aimed to compare the efficacy and safety of GEM-based combination therapy versus GEM alone in the treatment of advanced pancreatic cancer. DATA SOURCES: A comprehensive search of literature was performed using PubMed, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials...
June 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28602054/the-role-of-consolidation-chemo-radiotherapy-in-locally-advanced-pancreatic-cancer-receiving-chemotherapy-an-updated-systematic-review-and-meta-analysis
#13
Jeffrey S Chang, Yen-Feng Chiu, Jih-Chang Yu, Li-Tzong Chen, Hui-Ju Ch'ang
Purpose: The role of consolidation chemoradiation (CCRT) after systemic chemotherapy in locally advanced pancreatic cancer (LAPC) is still controversial. We aim to evaluate the effectiveness of CCRT in LAPC using systematic review and meta-analysis of prospective studies. Materials and Methods: Prospective clinical trials of LAPC receiving chemotherapy with or without subsequent CCRT were included in the analysis. We systematically searched in PubMed, Medline, Embase, Web of Science...
June 9, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28600474/use-of-angiotensin-system-inhibitors-is-associated-with-immune-activation-and-longer-survival-in-non-metastatic-pancreatic-ductal-adenocarcinoma
#14
Hao Liu, Kamila Naxerova, Matthias Pinter, Joao Incio, Hang Lee, Kohei Shigeta, William W Ho, Jonathan A Crain, Alex Jacobson, Theodoros Michelakos, Daniella Dias-Santos, Andrea Zanconato, Theodore S Hong, Jeffrey W Clark, Janet E Murphy, David P Ryan, Vikram Deshpande, Keith D Lillemoe, Carlos Fernandez-Del Castillo, Michael Downes, Ronald M Evans, James Michaelson, Cristina R Ferrone, Yves Boucher, Rakesh K Jain
Angiotensin system inhibitors (ASIs) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant chemotherapy in resected PDAC patients.<br /><br />Experimental Design: We performed an analysis of the records of ASI users and non-user patients with PDAC seen at Massachusetts General Hospital between January 2006 and December 2010. To identify mechanisms of ASIs in PDAC, we performed RNA-Seq of resected primary lesions...
June 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28599481/prognostic-impact-of-carbohydrate-sulfotransferase-15-in-patients-with-pancreatic-ductal-adenocarcinoma
#15
Zensho Ito, Kazuki Takakura, Machi Suka, Tomoya Kanai, Ryota Saito, Shuichi Fujioka, Mikio Kajihara, Hiroyuki Yanagisawa, Takeyuki Misawa, Tadashi Akiba, Shigeo Koido, Toshifumi Ohkusa
Patients with pancreatic ductal adenocarcinoma (PDA) typically succumb to mortality early, even following surgical resection. Therefore, prognostic factors associated with early mortality are required to improve the survival of patients with PDA following surgical resection. Carbohydrate sulfotransferase 15 (CHST15) is responsible for the biosynthesis of sulfated chondroitin sulfate E (CS-E), which serves a pivotal function in cancer progression by cleaving CD44. CHST15 and CD44 expression in PDA tissue were assessed as a prognostic factor in patients with PDA following surgical resection...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28599404/neoadjuvant-chemotherapy-for-pancreatic-cancer-effects-on-cancer-tissue-and-novel-perspectives
#16
Hidehiro Tajima, Isamu Makino, Yoshinao Ohbatake, Shinichi Nakanuma, Hironori Hayashi, Hisatoshi Nakagawara, Tomoharu Miyashita, Hiroyuki Takamura, Tetsuo Ohta
Chemotherapy for pancreatic cancer has diversified following the addition of more treatment regimens; however, in spite of this, pancreatic cancer remains a fatal disease. Preoperative (neoadjuvant) chemotherapy (NAC) or neoadjuvant chemoradiation therapy (NACRT) has been developed and implemented. For patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), a number of clinical trials have been conducted; NACRT was demonstrated to improve resectability, R0 resection rate, overall survival rate, disease-free survival rate and even an LAPC and BRPC survival advantage over NAC...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28591939/current-and-future-therapies-for-advanced-pancreatic-cancer
#17
REVIEW
Rohan Gupta, Idoroenyi Amanam, Vincent Chung
Pancreatic cancer remains a deadly disease with a 5-year survival rate of only 8%. Even after surgical resection, most patients have recurrence of their cancer. Over the last 10 years, improvements in chemotherapy regimens led to a doubling in median overall survival. Here we review the management of advanced pancreatic cancer and highlight vaccine therapy as a novel modality of treatment.
June 7, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28591817/efficacy-of-radiotherapy-for-primary-tumor-in-patients-with-unresectable-pancreatic-neuroendocrine-tumors
#18
Tomoyuki Iwata, Hideki Ueno, Jun Itami, Yoshinori Ito, Koji Inaba, Chigusa Morizane, Shunsuke Kondo, Yasunari Sakamoto, Satoshi Shiba, Mitsuhito Sasaki, Futa Koga, Takuji Okusaka
Background: Detailed information regarding the clinical efficacy of radiotherapy (RT) for primary tumor in patients with unresectable pancreatic neuroendocrine tumors (pNETs) is unknown. We therefore performed a retrospective study to evaluate the efficacy and safety of RT for primary pancreatic tumors in patients with pNETs. Methods: We investigated 11 patients with pNETs who received RT to the primary site between January 1997 and June 2015. Seven patients had Grade 2 neuroendocrine tumors (NET-G2) and four had neuroendocrine carcinoma (NEC) according to the 2010 WHO histopathological classification...
June 7, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28590776/clinical-effects-of-chemoradiotherapy-in-pursuit-of-optimal-treatment-of-locally-advanced-unresectable-pancreatic-cancer
#19
Kenta Sui, Takehiro Okabayashi, Yasuo Shima, Sojiro Morita, Jun Iwata, Tatsuaki Sumiyoshi, Yuichi Saisaka, Yasuhiro Hata, Yoshihiro Noda, Manabu Matsumoto, Akihito Nishioka, Tastuo Iiyama, Yasuhiro Shimada
OBJECTIVES: The treatment of locally advanced unresectable pancreatic cancer remains extremely challenging, particularly as the efficacy of concurrent chemoradiotherapy (CRT) remains unclear. METHODS: We studied 93 patients (8.0%) with locally advanced unresectable pancreatic cancer without distant metastases from among a total group of 1168 patients who were diagnosed with pancreatic cancer from March 2005 to November 2015 at Kochi Health Sciences Center. We therefore evaluated the clinical efficacy of CRT in patients with locally advanced unresectable pancreatic cancer...
June 7, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28588736/treatment-outcomes-of-concurrent-hyperthermia-and-chemoradiotherapy-for-pancreatic-cancer-insights-into-the-significance-of-hyperthermia-treatment
#20
Toshiya Maebayashi, Naoya Ishibashi, Takuya Aizawa, Masakuni Sakaguchi, Tsutomu Sato, Jiro Kawamori, Yoshiaki Tanaka
Patients with locally advanced unresectable pancreatic cancer (LAUPC) have a poor prognosis. In addition their quality of life impaired by cancer pain and biliary tract infections. Therefore, multimodality therapy and selection of optimal treatment methods are essential for achieving prolonged survival. The present study investigated the significance of using hyperthermia concurrently with multimodality therapy to improve treatment outcomes in patients with LAUPC. In total, 13 patients receiving concurrent hyperthermia and chemoradiotherapy (HCR) or chemoradiotherapy (CR) alone for LAUPC between 2002 and 2013 were analyzed retrospectively...
June 2017: Oncology Letters
keyword
keyword
66462
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"